PubMed Health⌕ Search

Biomedical subjects

C L Spurr

Publications and source records attributed to C L Spurr.

103 records · Page 6Linked to original sources

Complete deficiency of leukocyte glucose-6-phosphate dehydrogenase with defective bactericidal activity.

A 52 yr old Caucasian female (F. E.) had hemolytic anemia, a leukemoid reaction, and fatal sepsis due to Escherichia coli. Her leukocytes ingested bacteria normally but did not kill catalase positive Staphylococcus aureus, Escherichia coli, and Serratia marcescens. An H(2)O(2)-producing bacterium, Streptococcus faecalis, was killed normally. Granule myeloperoxidase, acid and alkaline phosphatase, and beta glucuronidase activities were normal, and these enzymes shifted normally to the phagocyte vacuole (light and electron microscopy). Intravacuolar reduction of nitroblue tetrazolium did not occur. Moreover, only minimal quantities of H(2)O(2) were generated, and the hexose monophosphate shunt (HMPS) was not stimulated during phagocytosis. These observations suggested the diagnosis of chronic granulomatous disease. However, in contrast to control and chronic granulomatous disease leukocytes, glucose-6-phosphate dehydrogenase activity was completely absent in F. E. leukocytes whereas NADH oxidase and NADPH oxidase activities were both normal. Unlike chronic granulomatous disease, methylene blue did not stimulate the hexose monophosphate shunt in F. E. cells. Thus, F. E. and chronic granulomatous disease leukocytes appear to share certain metabolic and bactericidal defects, but the metabolic basis of the abnormality differs. Chronic granulomatous disease cells lack oxidase activity which produces H(2)O(2); F. E. cells had normal levels of oxidase activity but failed to produce NADPH due to complete glucose-6-phosphate dehydrogenase deficiency. These data indicate that a complete absence of leukocyte glucose-6-phosphate dehydrogenase with defective hexose monophosphate shunt activity is associated with low H(2)O(2) production and inadequate bactericidal activity, and further suggest an important role for NADPH in the production of H(2)O(2) in human granulocytes.

Autoradiography↗

Phase I study of high-dose cytarabine and cisplatin in patients with advanced malignancy.

Nineteen patients with advanced malignancy participated in a phase I trial of high-dose cytarabine (ara-C) and cisplatin in combination. Dose and schedule were based on laboratory data indicating synergy for concurrent use of these drugs. Cisplatin (100 mg/m2) was administered during the 2nd and 3rd hours of a 3-hour ara-C infusion. The ara-C dose was escalated in subsequent patients following a starting dose of 1 g/m2. Two brief responses were noted. The study was terminated prematurely due to protracted (several weeks) nausea, occasional vomiting, and severe lassitude.

Adult↗

Pharmacokinetics of vincristine infusion.

Using a sensitive radioimmunoassay, serial blood concentrations of vincristine were measured in 11 patients with refractory malignancies receiving infusions of vincristine at three dose levels: 0.5, 0.75, and 1.0 mg/m2 daily for 5 days. The pharmacokinetics of vincristine infusion were compared to pharmacologic data obtained from four patients who received conventional iv bolus injections of 2 mg of vincristine. Whereas rapid decline of blood levels was seen following iv bolus injection, with concentrations of vincristine approaching 10(-9) M by 48-72 hours, vincristine infusions of 0.5, 0.75, and 1.0 mg/m2 daily for 5 days consistently resulted in blood concentrations greater than 10(-9) M during the treatment period. Similarly, areas under the concentration curve were greater in patients receiving infusions compared to bolus injections of vincristine. Antitumor responses in patients receiving vincristine infusions were observed after failure to respond to iv bolus injections. These data demonstrate the ability of infusion therapy to sustain blood concentrations of vincristine in man beyond that seen with conventional administration and suggest the possibility of improved therapeutic efficacy with this agent by use of infusion techniques.

Adult↗